Dopamine D, Receptors in the Rat Brain: Autoradiographic Visualization Using a High-Affinity Selective Agonist Ligand

Total Page:16

File Type:pdf, Size:1020Kb

Dopamine D, Receptors in the Rat Brain: Autoradiographic Visualization Using a High-Affinity Selective Agonist Ligand The Journal of Neuroscience, May 1987, 7(5): 1352-l 380 Dopamine D, Receptors in the Rat Brain: Autoradiographic Visualization Using a High-Affinity Selective Agonist Ligand C. Charuchinda,” P. Supavilai, M. Karobath, and J. M. Palacios Preclinical Research, SANDOZ LTD., CH-4002 Basle, Switzerland The non-catechol, selective dopamine D,-agonist compound component, one of the guanine-nucleotide binding proteins, a 3H-205-502 was used to localize dopamine D, receptors by G protein, to form what is called the “ternary complex” (Wreg- autoradiography after in vitro labeling of brain sections. The gett and Seeman,1983). This complex has beenparticularly well characteristics of the binding of this ligand to tissue sections characterized for dopamine D, receptors (Wreggett and de Lean, were those expected from the labeling of dopamine D, re- 1984) in the pituitary. ceptors. The binding of 3H-205-502 was inhibited selectively Some of theseligands have been usedfor the autoradiographic and stereospecifically by dopamine D, agents but not by localization of dopamine receptors after in vivo or in vitro la- dopamine D, compounds. beling (Palaciosand Wamsley, 1984; Kuhar et al., 1986; Palacios The autoradiographic localization of 3H-205-502 binding and Pazos, 1987). The most widely usedligand is 3H-spiperone, sites showed high densities of dopamine D, receptors in a ligand with limited receptor selectivity that, besidesdopamine areas such as the glomerular layer of the olfactory bulb, the D, and 5-HT, receptors, also binds with high affinity to a rec- nucleus accumbens, caudate-putamen, olfactory tubercle, ognition site without a known pharmacological role, the “spi- the lateral septum, and the islands of Calleja. Besides these rodecanone binding site” (Palacios et al., 1981; Altar et al., dopamine-innervated areas the substantia nigra and the 1985a, b). More recently, several 3H- and 1251-labeledbenzam- ventral tegmental area also showed important receptor den- ides have been introduced as selective D, ligands and utilized sities. Other areas where dopamine D, receptor binding was in receptor localization. These include ‘H-sulpiride (Jastrow et found were the stratum lacunosum-moleculare of the hip- al., 1984; Gehlert and Wamsley, 1985), 1251-sulpride(Martres pocampus, bands of labeling in the molecular layer of the et al., 1985a, b), 3H-(-)-D0 710 (Sokoloffet al., 1985), and 3H- 9th and 10th lobules of the cerebellum, and several com- eticlopride (Kiihler et al., 1986). A novel pyrroloisoquinoline, ponents of the visual system. 3H-R0 22-13 19 (piquindone; Nakajima and Iwata, 1984) has This distribution presents similarities and differences with also been used in autoradiographic experiments (Neck et al., previously reported distributions of dopamine D, receptors 1986). Finally, autoradiographic localization of dopamine re- visualized autoradiographically using 3H-labeled agonists and ceptors has been investigated with some 3H-labeled agonists, antagonists. In view of the high affinity, guanine nucleotide although satisfactory results have been obtained only with 3H- insensitivity, and dopamine D, selectivity of this agonist li- N-n-propylnorapomorphine (Fuxe et al., 1983; Scatton et al., gand, it is suggested that dopamine D, receptors exist in 1984; Dubois and Scatton, 1985; Dubois et al., 1986), 3H-apo- different states in different areas. 3H-205-502 appears to be morphine (Bouthenet et al., 1985) being a poor ligand. Recently, a new and useful tool for the study of dopamine D, receptors. 2 new non-catechol dopaminergic agonists with high affinity and selectivity for dopamine D, receptors have been described Many different radiolabeled moleculeshave been used to study (Closseet al., 1985; A. Closse,unpublished observations). These dopamine D, receptorsin the mammalian nervous system(See- ligands (&)205-50 1 [=(?)-N,N-diethyl-N’-[(3a,4a(u, lop)- 1,2,3, man, 1981; Creeseet al., 1983). The development of these dif- 4,4a, 5,lO,lOa - octahydro - 7 - hydroxy - 1 - propyl - 3 - benzo[g] ferent radioligands has been justified by their lack of pharma- quinolinyl]sulfamide] and the 6-hydroxy counterpart analog, cological selectivity for dopamine receptors or their subtypes- compound 205-502, are members of a new family of recently D, and D, (Kebabian and Calne, 1979)-and becauseof the synthesized dopamine agonistsstructurally related to apomor- poor technical properties of some of these ligands (i.e., high phine and to dopaminomimetic ergolines (Nordmann and nonspecific binding or poor chemical stability). The use of ra- Petcher, 1985). They exceed the receptor specificity of apo- diolabeled dopamine agonistshas presented special problems morphine, being selective D, agonists,and, as the ergolines,are becauseof the postulated existence of different affinity statesof long-lasting potent agonists. We have now used one of these the dopamine receptors (Creeseet al., 1984).3H-Agonists appear ligands, 3H-205-502, to visualize dopamine D, receptors in the to label predominantly a high-affinity state of the dopamine D, rat brain. receptor characterized by its high affinity for a third membrane Materials and Methods Rats (male Wistar, 180-250 g) were sacrificed by intracardial perfusion Received July 14, 1986; revised Oct. 30, 1986; accepted Nov. 10, 1986. with phosphate-buffered saline containing 0.1% formalin, after pento- We wish to thank Dr. D. Coward for a critical reading of the manuscript. barbital anesthesia (50 mg/kg). The brains were removed and frozen in Correspondence should be addressed to J. M. Palacios at the above address. liquid nitrogen. Tissue sections, 10 pm thick, were cut using a micro- a Submitted in partial fulfillment of the Ph.D. thesis, Faculty of Graduate Stud- tome-cryostat (Leitz 1720, from Leitz, Wetzlar, F.R.G.), mounted onto ies, Mahidol University, Bangkok, Thailand. gelatin-coated microscope slides and stored at -20°C until used. Copyright 0 1987 Society for Neuroscience 0270-6474/87/051352-09$02.00/O Slide-mounted rat brain sections were preincubated for 30 min in The Journal of Neuroscience, May 1987, 7(5) 1353 Table 1. Pharmacology of ‘H-205-502 binding to sections of the rat striatum Comnounds Dopamine agonists Dopamine 804.3 + 86.7 (3) Apomorphine 38.1 k 6.6 (3) Bromocriptine 28.1 zk 2.2 (3) LY 171 555 333.0 k 59.9 (3) (+)N-Propylnorapomorphine 1493.0 f 370.0 (3) (+)3-PPP 4485.0 2 913.0 (3) (-)3-PPP 386.3 f 61.5 (3) 'H-205-502 (nM) 205-501 50.9 t 1.8 (4) 205-502 5.5 + 0.6 (6) Figure 1. Concentration dependence of the binding of 3H-205-502 to rat brain striatal sections. SKF38393 6170.0 + 251.0 (3) Dopamine antagonists Spiperone 0.38 k 0.06 (3) 170 mM Tris-HCl buffer, pH 7.5, at room temperature, then incubated (+)Butaclamol 7.0 2 0.7 (3) for 90 min at room temperature in 170 mM Tris-HCl buffer, pH 7.5, (-)Butaclamol 15,000.0 * 1899.0 (3) with various concentrations (for saturation experiments) or 1 nM 3H- YM-09 15 l-2 0.47 + 0.02 (3) 205-502 and drugs as indicated. At the end of the incubation the slides were washed twice (1 min each) in 170 mM Tris-HCl buffer at 4°C. For SCH 23390 1977.0 k 700.0 (3) biochemical studies of 3H-205-502 binding, tissue was wiped from the Q Means f SEM. slide using a Whatman GF/B glass filter fiber and radioactivity deter- mined by liquid scintillation counting. Specific binding was calculated as the difference in radioactivity bound in the presence and absence of The specificity and selectivity of 3H-205-502 for dopamine 1 ELM (+)butaclamol. After the washing period, tissues were dried with cold air, and au- D, receptors were then examined. The binding of 3H-205-502 toradiograms were generated by apposing the labeled tissue to ‘H-Ul- to rat striatal sections was inhibited with high affinity by several trofilm (LKB, Sweden) as described by Unnerstall et al. (1982). Exposure dopamine agonists (Table l), including dopamine itself, apo- period was 60 d at 4°C. Brain gray and white matter standards containing morphine, bromocriptine, and the selective dopamine D, ago- known amounts of a nonvolatile 3H-labeled compound were exposed nist 205-501, unlabeled 205-502, and quinpirole (compound to the film along with the labeled tissue sections. Films were analyzed using a computerized image-analysis system that provides values of LY 17 1555; Tsuruta et al., 1981; Hahn et al., 1983). In contrast, receptor densities expressed in fmol/mg protein. Four to six bilateral the selective dopamine D, agonist SKF 38393 (Molloy and measurements were made per nucleus at the level described in each Waddington, 1984) showed only low affinity for the sites labeled animal, and the mean value was calculated. Values of “specific binding” by 3H-205-502. The inhibition of 3H-205-502 by dopamine for each rat were obtained by subtracting the nonspecific binding from agonists was stereospecific, with (+)iV-propylapomorphine and the total value. The mean value from equivalent areas in different an- imals was calculated. Results reported in this study are from at least 2 (+)3PPP showing affinities in the micromolar range (Table 1). separate experiments, involving tissues from 3 animals per experiment. Dopamine D, receptor antagonists were also potent displacers Brain nuclei were identified and named using the rat brain atlas of of 3H-205-502 binding. Again, the displacement was stereose- Paxinos and Watson (1982). lective, as shown by the differences in affinities exhibited by the 3H-205-502 (107 Ci/mmol) was synthesized and labeled by Dr. R. Voges of the Biopharmaceutical Department, Sandoz Ltd. (Basle, Swit- d- and l-stereoisomers of sulpit-ide and by (+) and (-) buta- zerland). Other chemicals or drugs were of commercial origin or kindly clamol. Selective D, antagonists such as YM-0915 l-2 (Grewe provided by the original manufacturers.
Recommended publications
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Equestrian Canada Drug Classification Scheme
    Equestrian Canada Drug Classification Scheme This Classification Scheme does not constitute a Prohibited List of banned substances not allowed in horses. Rather, it is designed to allow a hearing panel, after an equine medication violation has been determined, to determine the most appropriate sanction. The drugs, medications and types of substances listed under each Class are not exhaustive. The list in each Class provides examples of drugs, medications and types of substances with similar effects on a horse or that are considered equivalently serious when detected in a horse participating in an EC sanctioned competition. Sanctions will be imposed on a Class by Class basis. Class 1: - Substances which have no place in performing horses. Many of these compounds do not have legitimate medical uses in horses, and the remaining compounds would only be used for severely debilitated animals. Abuse of these compounds is of serious ethical (and many cases, legal) concern. - Most of these compounds are included in Schedules 1 and 3 of the Canadian Controlled Drugs and Substances Act (CDSA) - Examples of Class 1 drugs: o Opioids such as fentanyl, morpine, heroin and codeine o Cocaine o Amphetamine and its derivatives listed in Schedule 3 of the CDSA o Methylphenidate (Ritalin) o Methaqualone Class 2: - These compounds are not appropriate for use around the time of performance. Inappropriate use may alter the horse’s behaviour and ability to perform; medical use of these compounds indicates health status incompatible with athletic competition.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,197,764 B1 Bradley Et Al
    USOO6197764B1 (12) United States Patent (10) Patent No.: US 6,197,764 B1 Bradley et al. (45) Date of Patent: *Mar. 6, 2001 (54) CLOZAPINE COMPOSITIONS AND USES FOREIGN PATENT DOCUMENTS THEREOF 0599 576A1 1/1994 (EP). (75) Inventors: Matthews O. Bradley, Laytonsville, 693498 1/1996 (EP). MD (US); Victor E. Shashoua, 61204136 11/1984 (JP). Belmont, MA (US); Charles S. 06-072868 3/1994 (JP). Swindell, Merion; Nigel L. Webb, 6072868 3/1994 (JP). Bryn Mawr, both of PA (US) 7082146 3/1996 (JP). 8151334 6/1996 (JP). (73) Assignee: Protarga, Inc., Conshohocken, PA (US) 9030963 2/1997 (JP). (*) Notice: Subject to any disclaimer, the term of this WO 89/07938 9/1989 (WO). patent is extended or adjusted under 35 WO 96/04001 2/1996 (WO). U.S.C. 154(b) by 0 days. WO 96/22303 7/1996 (WO). WO 96/27380 9/1996 (WO). This patent is Subject to a terminal dis WO98/17325 4/1998 (WO). claimer. OTHER PUBLICATIONS (21) Appl. No.: 08/978,541 (22) Filed: Nov. 26, 1997 Bourat, et al., "Long Chain Esters of Pipotiazine as Lon g-Acting Psychotropic Pro-Drug, Med. Chem. Proc. Int. (51) Int. Cl. .............................................. A61K 31/00 Symp. 5th (1976) pp. 105-114. (52) U.S. Cl. ........................... 514/218; 514/219; 514/220 Lohr, et al., “Neuroleptic-Induced Movement Disorders . (58) Field of Search ..................................... 514/218, 219, ..", Psychiatry, vol. 3, (1989). 514/220 Makino, et al., Chemical Abstracts, vol. 106, No. 12, (56) References Cited (90.177x) issued Mar. 23, 1987, “Pharmaceuticals Permeable to Blood-Brain Barrier'.
    [Show full text]
  • TEXAS RACING COMMISSION January 28, 2021 To
    TEXAS RACING COMMISSION P. O. Box 12080, Austin, Texas 78711-2080 8505 Cross Park Drive, Suite 110, Austin, Texas 78754-4552 Phone (512) 833-6699 Fax (512) 833-6907 www.txrc.texas.gov January 28, 2021 To: Stewards, Commission Veterinarians, Test Barn Supervisors, Practicing Veterinarians, Owners, and Trainers From: Chuck Trout, Executive Director Re: Effective February 25, 2021 changes to the following documents: • Permissible Levels of Therapeutic Medications and Naturally Occurring Substances • Equine Medication Classification Policy and Penalty Guidelines • Equine Medication Classification List. This memo is to provide notice that the above listed documents are to be replaced effective this date. The changes include, but are not limited to: • Changes to the list of Permissible Levels of Therapeutic Medications and Naturally Occurring Substances; • Changes to the Equine Medication Classification Policy and Penalty Guidelines; • Changes to the Equine Medication Classification List. These documents are subject to further revision at any time. Test Barn Supervisors - please post this memo and the revised documents in the test barn as soon as possible. Also, please distribute copies of the Permissible Levels of Therapeutic Medications and Naturally Occurring Substances and Equine Medication Classification List to the practicing veterinarians at your racetrack. Licensing Staff - please post this memo and the revised documents where they may be viewed by the public as soon as possible. Copies of these documents will be made available on the Commission's website at http://www.txrc.texas.gov. Attachments: Permissible Levels of Therapeutic Medications and Naturally Occurring Substances Equine Medication Classification Policy and Penalty Guidelines Equine Medication Classification List TEXAS RACING COMMISSION P.
    [Show full text]
  • Dopamine Receptors on Prefrontal Neurons Department of Physiology
    THE KURUME MEDICAL JOURNAL SHORT COMMUNICATION VoI.36, p.151-154, 1989 Dopamine Receptors on Prefrontal Neurons HIDEKI YANO, EIICHIRO TANAKA, HIDEHO HIGASHI AND SYOGORO NISHI Department of Physiology and Institute of Brain Diseases, Kurume University School of Medicine, Kurume, 834 Japan Received for publication on October 16, 1989 Key words : dopamine receptors•\dopaminergic neurons•\dopamine•\recipient neurons•\prefrontal cortex•\nucleus accumbens Abnormalities in the cerebral dopamin- 400ƒÊm intervals. A fresh slice of the pre- ergic activity are involved in the etiology frontal region was transferred to a re - of schizophrenia (cf. Carlsson, 1988). Re- cording chamber and completely sub- cent studies on rodent brain slices revealed merged in a continuously flowing Krebs that the neurons in the nucleus accum- solution (37•Ž) gassed with 95% 02-5% bens which is one of the major structures C02 (Uchimura et al. 1986). Intracellular receiving the mesolimbic dopaminergic fi- recordings were obtained from neurons in bers are endowed with dopamine D 1 and and near the V th layer of the medial pre - D 2 (Kebabian and Calne, 1979) receptors frontal cortex. Recording electrodes were (Uchimura et al. 1986; Higashi et al. 1989), 3M K - acetate -filled glass micro-pipettes whereas that the substantia nigra neurons with tip resistances of 40 to 80MO, and which synthesize and release dopamine are connected to a high - input - impedance pre - endowed with dopamine D2 receptors amplifier (WPI M701). All drugs were ap - (Lacey et al. 1988). These studies also plied to the tissue by superf usion. The demonstrated that activation of the D 1 and neurons had resting membrane potentials D 2 receptors on accumbens neurons pro- of -70 to -80 mV and input resistances of duces hyperpolarization and depolariza- 40 to 60M0.
    [Show full text]
  • ARCI Uniform Classification of Foreign Substances
    DRUG TESTING STANDARDS AND PRACTICES PROGRAM. Uniform Classification Guidelines for Foreign Substances And Recommended Penalties Model Rule. September 2020 (V.14.2) © ASSOCIATION OF RACING COMMISSIONERS INTERNATIONAL – 2020. Association of Racing Commissioners International 2365 Harrodsburg Road, Suite B-450, Lexington, Kentucky USA 40504 www.arci.com Preamble to the Uniform Classification Guidelines of Foreign Substances The Preamble to the Uniform Classification Guidelines was approved by the RCI Drug Testing and Quality Assurance Program Committee (now the Drug Testing Standards and Practices Program Committee) on August 26, 1991. Minor revisions to the Preamble were made by the Drug Classification subcommittee (now the Veterinary Pharmacologists Subcommittee) on September 3, 1991. "The Uniform Classification Guidelines printed on the following pages are intended to assist stewards, hearing officers and racing commissioners in evaluating the seriousness of alleged violations of medication and prohibited substance rules in racing jurisdictions. Practicing equine veterinarians, state veterinarians, and equine pharmacologists are available and should be consulted to explain the pharmacological effects of the drugs listed in each class prior to any decisions with respect to penalties to be imposed. The ranking of drugs is based on their pharmacology, their ability to influence the outcome of a race, whether or not they have legitimate therapeutic uses in the racing horse, or other evidence that they may be used improperly. These classes of drugs are intended only as guidelines and should be employed only to assist persons adjudicating facts and opinions in understanding the seriousness of the alleged offenses. The facts of each case are always different and there may be mitigating circumstances which should always be considered.
    [Show full text]
  • 2021 Equine Prohibited Substances List
    2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s). Prohibited Substances that are identified as Specified Substances in the List below should not in any way be considered less important or less dangerous than other Prohibited Substances. Rather, they are simply substances which are more likely to have been ingested by Horses for a purpose other than the enhancement of sport performance, for example, through a contaminated food substance. LISTED AS SUBSTANCE ACTIVITY BANNED 1-androsterone Anabolic BANNED 3β-Hydroxy-5α-androstan-17-one Anabolic BANNED 4-chlorometatandienone Anabolic BANNED 5α-Androst-2-ene-17one Anabolic BANNED 5α-Androstane-3α, 17α-diol Anabolic BANNED 5α-Androstane-3α, 17β-diol Anabolic BANNED 5α-Androstane-3β, 17α-diol Anabolic BANNED 5α-Androstane-3β, 17β-diol Anabolic BANNED 5β-Androstane-3α, 17β-diol Anabolic BANNED 7α-Hydroxy-DHEA Anabolic BANNED 7β-Hydroxy-DHEA Anabolic BANNED 7-Keto-DHEA Anabolic CONTROLLED 17-Alpha-Hydroxy Progesterone Hormone FEMALES BANNED 17-Alpha-Hydroxy Progesterone Anabolic MALES BANNED 19-Norandrosterone Anabolic BANNED 19-Noretiocholanolone Anabolic BANNED 20-Hydroxyecdysone Anabolic BANNED Δ1-Testosterone Anabolic BANNED Acebutolol Beta blocker BANNED Acefylline Bronchodilator BANNED Acemetacin Non-steroidal anti-inflammatory drug BANNED Acenocoumarol Anticoagulant CONTROLLED Acepromazine Sedative BANNED Acetanilid Analgesic/antipyretic CONTROLLED Acetazolamide Carbonic Anhydrase Inhibitor BANNED Acetohexamide Pancreatic stimulant CONTROLLED Acetominophen (Paracetamol) Analgesic BANNED Acetophenazine Antipsychotic BANNED Acetophenetidin (Phenacetin) Analgesic BANNED Acetylmorphine Narcotic BANNED Adinazolam Anxiolytic BANNED Adiphenine Antispasmodic BANNED Adrafinil Stimulant 1 December 2020, Lausanne, Switzerland 2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s).
    [Show full text]
  • Drug/Substance Trade Name(S)
    A B C D E F G H I J K 1 Drug/Substance Trade Name(s) Drug Class Existing Penalty Class Special Notation T1:Doping/Endangerment Level T2: Mismanagement Level Comments Methylenedioxypyrovalerone is a stimulant of the cathinone class which acts as a 3,4-methylenedioxypyprovaleroneMDPV, “bath salts” norepinephrine-dopamine reuptake inhibitor. It was first developed in the 1960s by a team at 1 A Yes A A 2 Boehringer Ingelheim. No 3 Alfentanil Alfenta Narcotic used to control pain and keep patients asleep during surgery. 1 A Yes A No A Aminoxafen, Aminorex is a weight loss stimulant drug. It was withdrawn from the market after it was found Aminorex Aminoxaphen, Apiquel, to cause pulmonary hypertension. 1 A Yes A A 4 McN-742, Menocil No Amphetamine is a potent central nervous system stimulant that is used in the treatment of Amphetamine Speed, Upper 1 A Yes A A 5 attention deficit hyperactivity disorder, narcolepsy, and obesity. No Anileridine is a synthetic analgesic drug and is a member of the piperidine class of analgesic Anileridine Leritine 1 A Yes A A 6 agents developed by Merck & Co. in the 1950s. No Dopamine promoter used to treat loss of muscle movement control caused by Parkinson's Apomorphine Apokyn, Ixense 1 A Yes A A 7 disease. No Recreational drug with euphoriant and stimulant properties. The effects produced by BZP are comparable to those produced by amphetamine. It is often claimed that BZP was originally Benzylpiperazine BZP 1 A Yes A A synthesized as a potential antihelminthic (anti-parasitic) agent for use in farm animals.
    [Show full text]
  • FEI Prohibited Substances List
    FEI Prohibited Substances List This list of FEI prohibited substances will become current on 5th April 2010 at the same time as the FEI Equine Anti-Doping and Controlled Medication Regulations(EADCM) will also apply. The FEI Prohibted Substances List will be reviewed for suitability and any changes will be introduced on an annual basis. Please check www.fei.org for the latest version of this List. SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin Non-steroidal anti-inflammatory drug 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/antipyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic 8 Acetophenazine Antipsychotic 9 Acetophenetidin (Phenacetin) Analgesic 10 Acetylmorphine Narcotic 11 Adinazolam Anxiolytic 12 Adiphenine Antispasmodic 13 Adrafinil Stimulant 14 Adrenaline Stimulant 15 Adrenochrome Haemostatic 16 Aformoterol Bronchodilator 17 Alclofenac Non-steroidal anti-inflammatory drug 18 Alcuronium Muscle relaxant 19 Aldosterone Hormone 20 Alfentanil Narcotic 21 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 22 Almotriptan 5-hydroxatryptamine agonist (antimigraine) 23 Alphadolone acetate Neurosteriod 24 Alphaprodine Opiod analgesic 25 Alpidem Anxiolytic 26 Alprazolam Anxiolytic 27 Alprenolol Beta blocker 28 Althesin IV anaesthetic 29 Althiazide Diuretic 30 Altrenogest (in males and geldings) Oestrus suppression 31 Alverine Antispasmodic 32 Amantadine Dopaminergic 33 Ambenonium Cholinesterase inhibition 34 Ambucetamide Antispasmodic 35 Amethocaine Local anaesthetic 36 Amfepramone Stimulant 37 Amfetaminil Stimulant 38 Amidephrine Vasoconstrictor 39 Amiloride Diuretic 40 Amineptine Tricyclic antidepressant 41 Aminoglutehthamide Aromatase inhibitor 1 FEI Prohibited Substances List This list of FEI prohibited substances will become current on 5th April 2010 at the same time as the FEI Equine Anti-Doping and Controlled Medication Regulations(EADCM) will also apply.
    [Show full text]
  • (Amendment) 810 KAR 8:020. Drug, Medication, and Substance Classifica
    PUBLIC PROTECTION CABINET KENTUCKY HORSE RACING COMMISSION (Amendment) 810 KAR 8:020. Drug, medication, and substance classification schedule [and withdrawal guidelines]. RELATES TO: KRS 230.215, 230.225, 230.240, 230.260, 230.265, 230.290, 230.320, 230.370 STATUTORY AUTHORITY: KRS 230.215(2), 230.225, 230.240(2), 230.260, 230.320, 230.370 NECESSITY, FUNCTION, AND CONFORMITY: KRS 230.215(2) authorizes the Kentucky Horse Racing Commission (the “commission”) to promulgate administrative regulations prescribing conditions under which all legitimate horse racing and wagering thereon is conducted in Kentucky. KRS 230.240(2) requires the commission to promulgate administrative regulations restricting or prohibiting the administration of drugs or stimulants or other improper acts to horses prior to the horse participating in a race. This administrative regulation establishes the drug classification schedule in effect in Kentucky[and the withdrawal guidelines] for permitted drugs, medications, and substances that may be administered to race horses competing in Kentucky. Section 1. The Kentucky Horse Racing Commission Uniform Drug, Medication, and Sub- stance Classification Schedule.[, KHRC 8-020-1,] (1) This administrative regulation shall establish the respective classifications of all substances contained herein[therein. The Kentucky Horse Racing Commission Withdrawal Guidelines Thoroughbred; Standardbred; Quarter Horse, Appaloosa, and Arabian, KHRC 8-020-2, shall provide certain mandatory treatment requirements and guidance and advice on withdrawal intervals as contained herein]. (2)(a) Class A drugs, medications, and substances are those that: (1) Have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration; or (2) Lack approval by the United States Food and Drug Administration, but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration.
    [Show full text]
  • Uniform Classification Guidelines for Foreign Substances, Version 7.00
    Association of Racing Commissioners International, Inc. Drug Testing Standards and Practices Program Model Rules Guidelines Uniform Classification Guidelines for Foreign Substances and Recommended Penalties and Model Rule Version 7.00 Revised January 2014 Association of Racing Commissioners International, Inc. Uniform Classification Guidelines for Foreign Substances Table of Contents Preamble to the Uniform Classification Guidelines of Foreign Substances ..................................................................................... ii Notes Regarding Classification Guidelines ...................................................................................................................................... ii Classification Criteria ....................................................................................................................................................................... iii Classification Definitions ................................................................................................................................................................. iv Drug Classification Scheme ............................................................................................................................................................. vi Alphabetical Substance List ............................................................................................................................................................... 1 Listing by Classification ..................................................................................................................................................................
    [Show full text]